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a b s t r a c t
Background: The incidence of coronary artery disease (CAD) in Liver transplant (LT) patients is much
higher than prior estimates and the morbidity and mortality are significant in this group of patients.
Coronary angiography is the gold standard for detection of CAD, a non-invasive test that allows appropri-
ate risk stratification would be preferred. In this systematic review and meta-analysis, we sought to
assess the pooled diagnostic accuracy of various noninvasive cardiac imaging tests in detecting CAD in
patients listed for LT.
Methods: We performed a systematic review and meta-analysis of studies comparing sensitivity and
specificity of non-invasive tests to that of coronary angiography in diagnosing coronary artery disease
in patients undergoing liver transplantation.
Results: Five studies (616 participants) evaluated myocardial perfusion imaging (MPI); five studies (1243
participants) dobutamine stress echocardiography (DSE); and three (87 participants), other tests. MPI had
a pooled sensitivity of 0.62 (95% CI 0.37, 0.83), specificity of 0.60 (95% CI 0.39, 0.79), diagnostic odds ratio
(DOR) of 2.5 (95% CI 1.7, 5.64) and Area under the curve (AUC) 0.649. DSE had a pooled sensitivity of 0.25
(95%CI 0.09, 0.51), specificity of 0.68 (95% CI 0.44, 0.84) and DOR of 0.7 (95% CI 0.12, 3.84).
Conclusions: Our results show that both MPI and DSE are not effective screening tools for detecting CAD
in patients with end-stage liver disease (ESLD). Future studies are needed to evaluate the role of real-time
myocardial contrast echocardiography (RTMCE) and coronary artery calcium score (CAC) with coronary
CT angiography in patients with ESLD.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
A total of 8250 adult liver transplants (LT) were performed in
the United States (US) in 2018; 75.6% of all transplants were per-
formed in patients  50 years of which 23.4% were aged 65 years
or older [1]. The prevalence of coronary artery disease (CAD) is
considerable in this population. Recent reports suggest a higher
CAD prevalence in LT recipients than prior estimates [2]. CAD is
associated with increased mortality and morbidity in LT patients,
with a 1-year mortality as high as approximately 40% [2–4]. End-
stage liver disease (ESLD) is a state of high cardiac output, low sys-
temic vascular resistance, bradycardia; decreased responsiveness
to beta-adrenoceptor agonists, and increased circulating inflam-
matory mediators with cardio-depressant properties [4]. Cirrhotic
cardiomyopathy, present in 40–50% of patients with cirrhosis,
may be masked by reduced afterload and electrophysiological
abnormalities. Post LT, heart is suddenly exposed to altered hemo-
dynamics and stress [4–6]. While coronary angiography is the gold
standard for assessment of CAD, performing invasive cardiac
catheterization on all patients listed for LT is not cost-effective
and is associated with complications especially in patients with
coexisting renal dysfunction [7,8]. Non-invasive cardiac tests have
been used for detecting significant CAD and evaluating periopera-
tive risk in patients with ESLD. However, the optimal screening
method in this select group has not been defined. Currently, there
is no consensus among various society guidelines about which
non-invasive cardiac testing modality should be preferred for risk
stratification in these patients before LT. American Association
for the Study of Liver Diseases (AASLD) recommends use of non-
invasive stress echocardiography as the initial screening test and
invasive cardiac catheterization as clinically indicated (Grade 1B)
[9]. European Association for the Study of the Liver (EASL) recom-
mends electrocardiography and echocardiography in all patients
undergoing liver transplantations (Grade II-3). Further, EASL rec-
ommends cardiopulmonary exercise testing in patients with mul-
tiple risk factors and those older than 50 years. In patients
unable to achieve target heart rate during exercise testing, phar-
macological stress test is the test of choice (Grade II-3) [10]. In this
meta-analysis, we aim to assess the pooled diagnostic accuracy of
common noninvasive cardiac imaging tests in detecting CAD in
patients listed for LT.
2. Materials and methods
This systematic review and meta-analysis was conducted in
accordance to the Quality of Reporting of Meta-analysis statement
guidelines [11] and the PRISMA-DTA (Preferred Reporting Items for
a Systematic Review andMeta-analysis of Diagnostic Test Accuracy
Studies) Statement [12].
2.1. Search strategy
On May 10, 2020, a PubMed (MEDLINE) and EMBASE search
encompassing (cardiac evaluation techniques) OR (liver trans-
plantation) OR (coronary artery disease (CAD)) (Appendix 1)
was conducted, with no restriction on date and species-
specific search strategies and thesaurus were ratified such as
Medical Subject Heading terms and EMTREE for MEDLINE and
EMBASE respectively. To maximize the sensitivity of our search,
methodology filters were eschewed because even the aptly sen-
sitive filters deemed missing relevant articles [13,14].
2.2. Study selection
Two reviewers independently screened the titles, the
abstracts and the full text of the articles generated by literature
search. References of each included study were cross-checked
for other relevant studies. Inclusion criteria were retrospective
and prospective study designs reporting on cardiac test accu-
racy of the non-invasive test compared to coronary angiogra-
phy, the gold standard for CAD diagnosis. Almost all CAD
diagnostic tests were included entailing stress echocardiogra-
phy or myocardial perfusion imaging (MPI) (either exercise or
pharmacologically induced), exercise stress test (EST), electron
beam computerised tomography (EBCT), conventional echocar-
diography, digital subtraction fluorography (DSF), carotid
intima-medial thickness test (CIMT), CT coronary angiography,
magnetic resonance angiography, and cardiac magnetic reso-
nance imaging. Studies were approved as relevant if their par-
ticipants were candidates for LT meanwhile the diagnostic tests
were performed. Using coronary angiography as a standard, the
definition of coronary artery stenosis was at least 50% narrow-
ing of at least one epicardial coronary artery and severe coro-
nary artery stenosis was defined as having  70% stenosis.
Corresponding authors of studies that missed reporting 2x2
data tables were e-mailed for more information. Such studies
were excluded on failure to receive clarification from their cor-
responding authors after reminders.
3. Results
3.1. General information-selection of eligible studies
We screened 8278 titles and abstracts, 4962 from MEDLINE
and 3316 form Embase. Of those, we excluded 8199 reports dur-
ing the first phase of our selection process. During the second
phase (full-text review), we excluded 71 studies. The results
of electronic database searching are outlined in (Fig. 1). 19 stud-
ies met our inclusion criteria. However, only 10 studies were
eligible for the meta-analysis. Five studies compared DSE with
reference standard (coronary angiography), five studies com-
pared MPI with reference standard (coronary angiography).
Seven studies were not included in the meta-analysis as only
index test positive patients underwent coronary angiography
(Findely et al (2005), Biabhav et al (2017), Malik et al (2016),
Kong et al (2015), Kemmer et al (2014), Jodocy et al (2012),
Tsutsu et al (2006)) [15–21].
3.2. Characteristics of MPI studies
Three of five included studies of MPI were conducted in US. One
was conducted in Canada and the other in Turkey. Most studies
were performed at university hospital and were single center stud-
ies. The number of included patients in these studies ranged from
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32 to 293 (median, 93). Myocardial perfusion was evaluated using
technetium-99m (Tc-99m), thallium 201 or tetrofosmin isotopes
based upon the patient’s body mass index and chest diameter in
most studies. Most studies preferred exercise during stress testing
in all patients; however, patients who were unable to exercise
received intravenous dipyridamole. Only one study used adenosine
and regadenoson as vasodilator agents (Bhutani et al) [22].
MPI was compared with coronary angiography in five studies
(616 participants) (Alba 2013, Aydinalp 2009, Barker 2015, Bhutani
2013, and Davidson 2002) [23–26]. (Fig. 2). Using the univariate
model, the pooled sensitivity was 0.58 (95% CI 0.47, 0.68) and
specificity 0.68 (95% CI 0.63, 0.73). The pooled summary estimates
showed that MPI had a diagnostic odds ratio (DOR) of 2.3 (95% CI
1.46, 3.76) and area under the curve (AUC) 0.649. Using the bivari-
ate model, the pooled sensitivity 0.62 (95% CI 0.37, 0.83) and speci-
ficity 0.60 (95% CI 0.39, 0.79). MPI was associated with DOR of 2.50
(95% CI 1.17, 5.64). Three studies of five studies avoided partial ver-
ification bias. The pooled estimates of these studies were 0.44 (95%
CI 0.29, 0.60) for sensitivity and 0.75 (95% CI 0.70, 0.80) for speci-
ficity. The DOR remained unchanged at 2.49 (95% CI 1.30, 4.74) and
the AUC 0.739, with positive likelihood ratio of 1.74 (95% CI 1.23,
2.47) and negative likelihood ratio of 0.74 (95% CI 0.56, 0.97). There
is a substantial heterogeneity among the five studies (Fig. S3). One
study (Kremmer 2014) [17] was excluded from the meta-analysis
in which 4 participants with positive MPI underwent coronary
angiography. In this study, patients with a negative MPI were not
Fig. 1. Flow chart of studies selection during literature search.
Fig. 2. Forest of plot of myocardial perfusion imaging studies.
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subjected to the reference standard (coronary angiography); thus,
a true specificity could not be calculated.
We analyzed five studies using the MPI tool in a cumulative 616
patients awaiting liver transplant. Ayndinalp et al. prospectively
evaluated 93 liver transplantation candidates to determine the
sensitivity and specificity of MPI in the detection of CAD [24]. Only
reversible perfusion defects were considered positive; fixed defects
and normal perfusion were deemed negative. Their analysis
showed MPI to hold 100% sensitivity and 61% specificity for severe
CAD which in turn was defined as stenosis of 70% or greater or
greater than 50% with a positive MPI (reversible perfusion defects).
Davidson et al., on the other hand, reported the sensitivity of MPI
to be 37% with a specificity of 63% after retrospectively evaluating
83 liver transplantation candidates [26]. They also defined clini-
cally relevant CAD on coronary angiography as a stenosis of 70%
or greater, however, all single positron emission computed tomog-
raphy (SPECT) scans defects were interpreted as positive regardless
of size, severity, or reversibility (fixed or reversible). Alba et al.,
studied 115 patients undergoing MPI and coronary angiography
with positive test defined as having 1 or more area(s) of ischemia
seen on MPI and/or 50% or greater coronary artery stenosis on
angiography. The sensitivity and specificity of MPI to identify
CAD was found to be 66% and 52% respectively [23]. Bhutani
et al. retrospectively analyzed 414 patients with end-stage liver
disease who underwent coronary angiography and MPI before liver
transplantation [22]. Like Davidson et al., they had interpreted all
defects on MPI as positive regardless of size, severity, or reversibil-
ity. All the above studies included in our analysis evaluated pre-
liver transplant patients with no known history of CAD and all
patients underwent MPI followed by coronary angiography regard-
less of the MPI results. The main difference among the studies
however was the interpretation/definition of a positive MPI test.
This probably explains the variability in their results. In the fifth
study by Baker et al., 244 patients with advanced liver disease were
divided into 3 study cohorts; those with a positive MPI, those with
a negative MPI, and those with the negative MPI having coronary
angiography [25]. Our analysis included only those patients who
underwent both MPI as well as coronary angiography (n = 32; pos-
itive MPI = 26, negative MPI = 6); outcome being MPI with a sensi-
tivity of 91% and a specificity of 24%.
3.3. Characteristics of DSE studies
All of the included studies were conducted in US and performed
at single center university hospitals. The number of included
patients were ranged from 18 to 64 (median, 59 Three of these
were retrospective and one was prospective. All studies only
enrolled the patients who are candidates for liver transplantation
and were referred for cardiac evaluation for suspected CAD. DSE
was performed according to institutional protocol, with intra-
venous dobutamine infusion administered at incremental doses
until the target heart rate or study end point were achieved.
Five studies (1243 participants) identified DSE (Donovan 1996,
Harinstein 2008, Sinpelisky 2014, Doytchinova 2019, Kutkut 2019)
[27–31]. Presence of wall motion abnormalities during the stress
test was considered a positive result for diagnosing CAD (Fig. 3).
The pooled sensitivity of DSE was 0.27 (95% CI 0.07, 0.12) and
the pooled specificity was 0.88 (95% CI 0.71, 0.78). Generally, DSE
was associated with DOR of 0.79 (95% CI 0.06, 9.76). Using the
bivariate model, the pooled sensitivity 0.25 (95% CI 0.09, 0.51)
and specificity 0.68 (95% CI 0.44, 0.84). DSE was associated with
DOR of 0.7 (95% CI 0.12, 3.84). All five studies used a reference test
diagnostic threshold of 50% stenosis. Generally, there was a
strong evidence of heterogeneity (Fig. 4S) among these five studies.
Four records (60 participants), weren’t included in the meta-
analysis (Plotkin, Baibhav, Malik, Findlay) [3,15,19,21], as in these
studies, patients with a negative DES were not subjected to the ref-
erence standard (coronary angiography); thus, a true specificity
could not be calculated.
Five studies were included in our analysis that endorsed DSE as
a preferred cardiac test, in a pooled population of 1243 patients. As
with our MPI study selection criteria, our objective was to identify
patients who underwent both the screening as well as the gold
standard test in order to extrapolate the sensitivity and specificity
data. Donovan et al. evaluated 165 patients with ESLD, suitable for
liver transplantation, who underwent DSE as part of pre-operative
cardiac assessment [27]. Only 11 patients were noted to have wall
motion abnormality, and out of those 9 patients underwent coro-
nary angiography. Cardiac catheterization was also performed in
9 patients without a notable ischemic response on DSE. Only 3
patients in the former group had coronary stenosis of 50% or
greater. In the latter group, only one patient had significant coro-
nary artery stenosis, thereby yielding a sensitivity of 75% and a
specificity of 57% were observed which could be limited by extre-
mely small study group (n = 18). In a retrospective analysis of 105
liver transplant candidates who had both DSE and angiography,
Harinstein et al. observed sensitivity and specificity of DSE to be
17% and 88% respectively in CAD with obstruction >50% or greater.
Only 64 patients who were able to meet target heart rate on DSE
and who did not have prior history of CABG, were included in
the primary study group [28]. Snipelisky and colleagues identified
a cohort of 64 patients who underwent angiography within 1 year
of DSE. Catherization results were classified as mild (<50% steno-
sis), moderate (50–70% stenosis), and severe (>70% stenosis). Out
of 38 patients with regional wall abnormalities seen on DSE, only
12 patients were found to have moderate to severe CAD, while
16 patients had mild CAD. On the other hand, out of 35 patients
with non-ischemic DSE results, 17 had documented stenosis of
more than 50% on cardiac catheterization. The analysis showed a
sensitivity of 41% and a specificity of 47% [29]. In a retrospective
study by Doytchinova et al, data from 633 liver transplantation
candidates was analyzed to determine the test performance of
DSE in end stage liver disease. Patients with positive or equivocal
DSE or with a normal test in the presence of risk factors were
referred for coronary angiography. Beta blocker was held 3 days
prior to the DSE, and atropine was administered either during
the rest and/or the stress phase of the test, in order to achieve
the target heart rate. The study analysis yielded a sensitivity and
specificity of 19% and 90% respectively of DSE in detecting CAD
with obstruction >50% or greater. The sensitivity of DSE in this
Fig. 3. Forest of plot of dobutamine stress echocardiography studies.
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study was again low and did not improve after attaining the target
heart rates [34]. Another recently published retrospective analysis
conducted by Kutkut et al., showed a sensitivity of DSE to be 37% in
detecting significant CAD in ESLD patients. Out of the 41 patients
who were subsequently diagnosed with CAD on angiography, 15
were screened positive and 26 had a negative DSE. There were
378 patients who had normal DSE and cardiac catheterization.
Only 48 patients had false positive results with DSE yielding a
specificity of 89% [35].
4. Discussion
Our results show that MPI has a higher overall sensitivity and
accuracy, though modest, compared to DSE. Both the tests, on
the other hand, are found to have comparable, statistically signifi-
cant, moderate specificities. There was no good data to assess the
validity of other tests, like the coronary artery calcium (CAC) score
or coronary CT angiography compared with the gold standard inva-
sive coronary angiography, in patients awaiting liver transplant.
Another promising test modality that brings in the use of both per-
fusion imaging and the DES is the RTMCE that appears to be a use-
ful tool in predicting cardiovascular mortality in patients with
advanced liver disease.
A high heterogeneity was observed in the pooled analysis of
both MPI and DSE testing and is likely due to lack of a reference
standards. Several artefacts and interpretation pitfalls can poten-
tially compromise MPI results. Moreover, the hemodynamic
changes seen in patients with liver disease may confound the
results of MPI in this select group of patients, however to a lesser
degree when compared to DSE. Firstly, the MPI relies on myocar-
dial perfusion and not on inducible ischemia to detect coronary
artery disease. As is understood from the physiological standpoint,
advanced liver disease causes a perennial state of vasodilation. This
may hinder additional adenosine-induced vasodilatation and can
potentially decrease the diagnostic yield of MPI in liver disease
patients. Secondly, the interpretation is dependent on both the size
and intensity of the defect. However, in most of the studies, MPI
scan defects were interpreted as positive regardless of size, sever-
ity, or reversibility (fixed or reversible).
DSE is one of the standard diagnostic modalities for chest pain
evaluation and pre-operative risk assessment when evaluating
unselected patients for ischemic heart disease. The sensitivity of
DSE is directly proportional to the maximal heart rate achieved
during the stress. The use of beta-blocking agents like propranolol,
in patients with advanced liver disease, can result in an inability to
achieve target heart rates making DSE an ineffective screening tool
in this patient population. Low sensitivity of the DSE in patient
undergoing liver transplant evaluation in our analysis is consistent
with the observations published by Nguyen et al. [32] as well with
the ACC/AHA guidelines [33]. Also, the high variability in the
results in the studies included can be attributed to the operator
dependency, both with respect to data acquisition and test inter-
pretation. Besides the operator dependency and lack of a reference
standard, the heterogeneity in the sensitivity and specificity
amongst the selected studies could have resulted from a selection
bias, duration of follow-up, prevalence of CAD in different centers
and in different points in time, as well as the etiology of the liver
disease. DSE sensitivity in the study by Doytcinova et al was calcu-
lated to be 16.3% (n = 8/49) in patients analyzed in early years of
the study versus 39.1% (n = 9/23) when the analysis was performed
for patients admitted in the recent years. As we know, the preva-
lence of CAD is on the rise in the general population and as well
as in advanced liver disease patients. Also, there is a higher preva-
lence of CAD in patients with advanced liver disease from non-
alcoholic steatohepatitis (NASH), compared to those from other
etiologies, and whose prevalence is steadily rising in conjunction
with the obesity epidemic [34]. Thus, the older studies may have
a lower prevalence of CAD and differing etiologies of liver diseases
compared to the newer ones. In addition, there is an increasing
number of patients receiving liver transplants at a more advanced
age due to improvements in surgical techniques, organ preserva-
tion, and perioperative care, together with a sizeable number of
deceased and living donors entering the transplant pool [35].
Dobutamine stress real-time myocardial contrast echocardiog-
raphy (RTMCE) has the capability of quantifying both myocardial
blood volume and velocity on a regional basis. It can thereby mea-
sure ’relative’ reduction in myocardial perfusion (a product of
myocardial blood volume and velocity) using myocardial contrast
parameters, at both rest and during reversible ischemia generated
by stress [36]. In addition, RTMCE is able to delineate subendocar-
dial wall-thickening abnormalities, thereby improving the sensi-
tivity of wall motion analysis during stress [37]. Porter et al., in a
prospective trial, found RTMCE to be a better modality for detect-
ing resting wall motion abnormalities when compared to DSE [38].
DSE can only analyze transmural wall thickening, whereas the
RTMCE can detect wall thickening abnormality confined to the
sub-endocardium, even in patients who have apparent normal
transmural wall thickening during stress [38]. When compared to
MPI, RTMCE can be performed at the bedside and provides quick
interpretation by assessing both the perfusion and the contractility
simultaneously and in real time. It also provides better quantifica-
tion of LV volume and high resolution images when compared to
the conventional MPI, obviating the exposure to radiation, thereby
standing out as a promising modality [39]. This is complemented
by the results of our statistical analysis that indicate that the DSE
and MPI obtained by myocardial scintigraphy are of limited use
as a screening tool in patients with ESLD.
Another imaging modality, which is non-stress based is CAC and
coronary CT angiography. CAC values >400 has been associated
with worse cardiac outcome after LT [40], but there have been sev-
eral confounders such as DM, advance age, associated with high
CAC. Although CAC scoring has emerged as a widely available, con-
sistent, and reproducible means of assessing risk for major cardio-
vascular outcomes, more studies are required to assess the
predictive value of CAC for perioperative outcomes in LT patients.
Coronary CT angiography requires slow heart rate, absence of
arrhythmia and normal renal function but requires contrast
administration. Patients with ESLD often have coexisting renal
impairment. In normal population, a normal coronary CT angiogra-
phy effectively excludes obstructive CAD, but routine pre-
operative coronary CT angiography has a low yield in LT patients
[41]. There have been no previous studies to determine the diag-
nostic accuracy of coronary CT angiography with invasive coronary
angiography for the detection of CAD in LT recipients.
5. Limitations
Although our review could identify only 5 studies involving DSE
and 5 studies involving MPI, all of these were carefully selected to
avoid any negative impact on our pooling model. We were consci-
entious and deliberate about our study selection and consequently
may have compromised on the sample size. However, it was
imperative that we select specific studies that were well-
conducted, reproducible, transparent, and had an unpretentious
statistical analysis in line with our strict and rigorous inclusion cri-
teria. We also aimed at avoiding the small study effect by removing
publication bias and employed well-established statistical meth-
ods to counter heterogeneity and variability. Another limitation
is the inability to stratify pooled analysis based on individual eti-
ologies of the end stage liver disease such as NASH vs Hepatitis C
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and other comorbidities such as end-stage renal disease. These
underlying and co-existing conditions have been known to con-
tribute to the development of CAD.
6. Conclusions
In conclusion, the results of our systematic review show that
both, MPI and DSE, are ineffective screening tools for detecting
CAD in patients undergoing liver transplant evaluation. We also
re-iterate the need for further studies to evaluate the role of
RTMCE, CAC and/or coronary CT angiography in patients with
advanced liver disease, which appear to be a promising and poten-
tially a more reliable future modality. With the advent of effica-
cious HCV treatment and ever-rising incidence of obesity and
diabetes, we foresee an upward shift in the proportion of patients
with advanced age and non-alcoholic steatohepatitis being evalu-
ated for transplant surgery, and consequently, there is an emergent
need for an optimal screening method in this select group.
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